Sangamo Therapeutics Inc (SGMO) - Total Liabilities
Based on the latest financial reports, Sangamo Therapeutics Inc (SGMO) has total liabilities worth $82.40 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Sangamo Therapeutics Inc (SGMO) cash conversion ratio to assess how effectively this company generates cash.
Sangamo Therapeutics Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how Sangamo Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Sangamo Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Sangamo Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sangamo Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Societe de Tayninh SA
PA:TAYN
|
France | €86.44K |
|
Kwang Ming Silk Mill Co Ltd
TWO:4420
|
Taiwan | NT$231.41 Million |
|
Luxury Real Estate Investment Fund
BK:LUXF
|
Thailand | ฿76.63 Million |
|
Taiwan Alpha Electronic Co Ltd
TWO:6204
|
Taiwan | NT$157.31 Million |
|
Sunview Group Bhd
KLSE:0262
|
Malaysia | RM334.30 Million |
|
Duck Yang Ind
KO:024900
|
Korea | ₩452.87 Billion |
|
As Commercial Industrial Company of Computers and Toys S.A.
AT:ASCO
|
Greece | €7.19 Million |
|
Sharps Technology Inc
NASDAQ:STSS
|
USA | $10.75 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down Sangamo Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SGMO stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 13.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sangamo Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sangamo Therapeutics Inc (1996–2024)
The table below shows the annual total liabilities of Sangamo Therapeutics Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $78.86 Million | -4.33% |
| 2023-12-31 | $82.43 Million | -69.19% |
| 2022-12-31 | $267.55 Million | -22.80% |
| 2021-12-31 | $346.58 Million | -21.44% |
| 2020-12-31 | $441.18 Million | +115.45% |
| 2019-12-31 | $204.78 Million | -8.53% |
| 2018-12-31 | $223.88 Million | +126.50% |
| 2017-12-31 | $98.84 Million | +355.57% |
| 2016-12-31 | $21.70 Million | -12.50% |
| 2015-12-31 | $24.80 Million | -32.21% |
| 2014-12-31 | $36.58 Million | +91.23% |
| 2013-12-31 | $19.13 Million | +8.45% |
| 2012-12-31 | $17.64 Million | +144.82% |
| 2011-12-31 | $7.20 Million | +1.58% |
| 2010-12-31 | $7.09 Million | -54.70% |
| 2009-12-31 | $15.66 Million | +25.72% |
| 2008-12-31 | $12.45 Million | +5.74% |
| 2007-12-31 | $11.78 Million | +66.47% |
| 2006-12-31 | $7.08 Million | -36.66% |
| 2005-12-31 | $11.17 Million | +375.68% |
| 2004-12-31 | $2.35 Million | +49.46% |
| 2003-12-31 | $1.57 Million | -20.70% |
| 2002-12-31 | $1.98 Million | -25.75% |
| 2001-12-31 | $2.67 Million | +31.11% |
| 2000-12-31 | $2.04 Million | +56.54% |
| 1999-12-31 | $1.30 Million | +107.01% |
| 1998-12-31 | $628.00K | +28.95% |
| 1997-12-31 | $487.00K | +363.81% |
| 1996-12-31 | $105.00K | -- |
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a ch… Read more